Background: Moxifloxacin retains partial activity against some fluoroquinolone-resistant mutants of Mycobacterium tuberculosis. Levofloxacin is presumed to be as active as moxifloxacin against drug-susceptible tuberculosis and to have a better safety profile.
Introduction
Misuse of antibiotics has led to the appearance of multidrugresistant tuberculosis (MDR TB), defined as resistant to at least isoniazid and rifampicin. 1 Since fluoroquinolones (FQs) and aminoglycosides have been used widely to treat these MDR TB cases, additionally FQ-and aminoglycoside-resistant MDR TB strains have been selected, leading to extensively drug-resistant tuberculosis (XDR TB) strains. The WHO reported approximately 480000 new cases of MDR TB in 2014, including 10% that were XDR TB. 2 The prognosis of MDR and XDR TB is poor since the death rate increases from 10%, in drug-susceptible tuberculosis, to at least 17%-24% and 23%-61% in MDR and XDR TB, respectively.
3,4 FQ resistance appears to be the main factor explaining the poor prognosis of XDR TB. 5 The main mechanism of FQ resistance in Mycobacterium tuberculosis relies on DNA gyrase mutations, which cause variable levels of resistance. We have shown in previous work in mice that a human equivalent dose of 400 mg/day moxifloxacin retains partial activity against FQ-resistant M. tuberculosis mutants. 6 We subsequently showed that this benefit was maintained against low-level FQ-resistant strains when moxifloxacin was used in combination with second-line drugs. 7 This concept of using an FQ despite in vitro resistance was validated in a clinical V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. study in which gatifloxacin, as part of the 9 month Bangladesh regimen, was as active against low-level-resistant strains as against FQ-susceptible strains. 8 Levofloxacin, another FQ with antituberculous activity, has shown higher early bactericidal activity (EBA) at 1000 mg/day than moxifloxacin and gatifloxacin at 400 mg/day. 9 When included in an anti-MDR TB regimen, levofloxacin at 750 mg/day has proven to be equivalent to moxifloxacin at 400 mg/day, with the 3 month sputum culture conversion rate taken as the criterion of effectiveness. 10 More importantly, levofloxacin has a better safety profile than moxifloxacin and gatifloxacin. 9 In particular, levofloxacin prolongs the QT interval less than moxifloxacin, which makes it the preferred FQ for combination with drugs that do prolong the QT interval, for instance, new anti-TB drugs such as bedaquiline or delamanid, or also clofazimine which is part of the short MDR TB treatment recently approved by the WHO. 11 Therefore, WHO recommendations proposed levofloxacin as the preferred FQ to be included in an anti-MDR TB regimen. However, levofloxacin activity has never been evaluated against FQ-resistant strains.
Our objective was to compare the in vivo activities of levofloxacin and moxifloxacin against wild-type (WT) M. tuberculosis and strains harbouring DNA gyrase mutations responsible for various levels of FQ resistance, using a murine model of infection.
Materials and methods

Antimicrobial agents
Solutions were prepared from tablets of moxifloxacin (400 mg; BayerV R ) and levofloxacin (500 mg; Arrow Génériques V R , Lyon, France). Tablets were crushed in a mortar and dissolved in sterile water at the desired concentration to provide a gavage solution. Levofloxacin and moxifloxacin powders (Sigma-Aldrich, France) were used to determine MICs.
M. tuberculosis strains
Four M. tuberculosis strains were used, the WT reference strain H37Rv and three isogenic mutant strains harbouring DNA gyrase substitutions: A90V in GyrA and two GyrB mutants selected in vivo. The latter two harbour the E540A and A543V mutations according to the numbering system used more frequently in the literature, or E501A and A503V according to the recently proposed consensus numbering system for GyrB. 12 M. tuberculosis strains were isolated from mice lungs and grown on Lowenstein-Jensen medium. 13 The mutation present in each strain was checked by sequencing the gyrA and gyrB quinolone resistance determining regions as previously described. 6 
Determination of MICs
The MICs of ofloxacin, moxifloxacin, gatifloxacin, levofloxacin and enoxacin were determined using 7H11 agar supplemented with 10% OADC. MIC was defined as the lowest concentration that inhibited .99% of bacterial growth.
Murine model of tuberculosis
Five-week-old inbred BALB/c mice were purchased from the Janvier Breeding Center (Le Genest Saint-Isle, France). Mice were inoculated in the tail vein with a 0.5 mL bacterial suspension that contained 5.7-6.0 log 10 cfu of each M. tuberculosis strain. A first experiment aimed at comparing the virulence of M. tuberculosis H37Rv WT and mutant strains harbouring substitutions in DNA gyrase. We inoculated three mice for each strain and monitored them for 1 month. A second experiment aimed at comparing the residual efficacies of moxifloxacin and levofloxacin against the FQresistant mutants and against the WT strain. We conducted this experiment twice, with 160 mice inoculated in each case and with two sets of FQ doses: first with levofloxacin at 50 mg/kg q6h and moxifloxacin at 66 mg/kg q6h; and second with levofloxacin at 100 mg/kg q6h and moxifloxacin at 60 mg/kg q6h. Mice were treated for 5 days per week over 4 weeks.
For each experiment and each M. tuberculosis strain (H37Rv WT and mutant strains GyrA A90V, GyrB E540A and GyrB A543V), 40 mice were inoculated: 10 to determine the initial bacillary load in lungs (D0), 10 for survival analysis and 10 to assess the treatment efficacy of moxifloxacin and levofloxacin. The moxifloxacin doses used aimed to mimic the human equivalent 400 and 800 mg/day doses; the levofloxacin doses used aimed at to mimic the 750 and 1000 mg/day doses. 9, [14] [15] [16] [17] [18] Since the optimal AUC 0-24 /MIC ratio of levofloxacin against M. tuberculosis was unknown, we added a dose-ranging evaluation against H37Rv during the second experiment. We treated six H37Rv-infected mice with 25 mg/kg levofloxacin and six with 35 mg/kg, given by oral gavage q6h, 5 days per week over 4 weeks.
Ethics
The study was approved by the Charles Darwin Research Ethics Committee (approval number 45682016031411142463 v3).
Assessment of efficacy
Treatment efficacy was measured in terms of survival rates and lung cfu counts. Ten mice from each treatment group were sacrificed 1 day after infection (D0). Surviving mice were sacrificed at the completion of treatment. The bacillary load was compared between end and start of treatment. When there was a statistically significant decrease, the activity was considered bactericidal. When the bacillary load was not statistically different from that at the start of treatment, the activity was considered bacteriostatic.
Levofloxacin and moxifloxacin dose-effect model
Non-linear regression analysis using a sigmoid E max effect model 19 was done based on bacterial concentrations in the lung after 4 weeks of treatment. Dose-effect sigmoid curves were drawn using the following Hill equation: bactericidal effect " E max /{1!10 exp[(log EC 50 -x) % N]}, where EC 50 is the 50% effective exposure, x is the antibiotic C max and N is the Hill coefficient. FQ exposure was expressed in C max /MIC and AUC 0-24 /MIC ratios.
Statistical analysis
We compared cfu counts using the non-parametric Wilcoxon test and evaluated survival data using the log-rank test. Statistical calculations were done using the website BiostaTGV (http://www.u707.jussieu.fr/biostatgv/). In the dose-effect model, levofloxacin and moxifloxacin effects were compared using the non-parametric Wilcoxon and Spearman tests. Calculations were done using SigmaPlot V R software. Differences were considered statistically significant when P , 0.05.
Pharmacokinetic analysis in mice
We measured the pharmacokinetic parameters of each moxifloxacin and levofloxacin dose after the first dose was administered. Once the drug was administered orally, we anaesthetized the mice with isoflurane. We collected blood by performing cardiac puncture in three mice for each time point. Blood was drawn 0, 10, 20, 30, 90, 240 and 360 min after gavage. The total fractions of levofloxacin and moxifloxacin were measured using a microbiological assay with Escherichia coli as the assay organism. 20 We determined the C max and AUC in a compartmental and a non-compartmental model using Phoenix V R software. Drug
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JAC accumulation was assessed by determining the residual plasma concentrations in three mice after 7, 14 and 21 days of treatment.
Results
Characteristics of FQ-resistant strains of M. tuberculosis
Levofloxacin and moxifloxacin MICs were, respectively, 0.25 and 0.25 mg/L for the WT strain H37Rv, 0.5 and 0.5 mg/L for the GyrB E540A mutant, 1 and 0.5 mg/L for the GyrB A543V mutant, and 4 and 2 mg/L for the GyrA A90V mutant (Table 1) .
Pharmacokinetic analysis in mice
Since the AUC/MIC ratio is believed to be the pharmacodynamic driver of FQ activity against M. tuberculosis, 21 50 and 100 mg/kg q6h levofloxacin in mice were considered to be equivalent to, respectively, 750 and 1000 mg/day in humans (Tables 2 and 3 ). For moxifloxacin, 60 and 66 mg/kg q6h in mice were considered to be equivalent to, respectively, 400 and 800 mg/day in humans. Weekly monitoring of residual moxifloxacin and levofloxacin concentrations did not show any accumulation of these drugs.
Virulence of FQ-resistant M. tuberculosis strains
Mice were infected with inocula ranging from 5.7 to 6.0 log 10 cfu. Mortality of untreated H37Rv-infected mice was not different from that of mice infected with mutant strains (P . 0.22) in the two experiments (data not shown).
Comparison of levofloxacin and moxifloxacin activities against FQ-resistant M. tuberculosis Survival analysis
A 50 mg/kg q6h levofloxacin dose prevented mortality in GyrB E540A-infected mice (P " 0.02) and delayed mortality in GyrB A543V-infected mice (P " 0.02) but not in GyrA A90V-and H37Rv-infected mice ( Figure S1 , available as Supplementary data at JAC Online). A 100 mg/kg q6h levofloxacin dose prevented mortality in H37Rv-, GyrB E540A-and GyrB A543V-infected mice (P , 10
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) but not in GyrA A90V-infected mice (P " 0.07) ( Figure S2 ). A 60 mg/kg q6h moxifloxacin dose prevented mortality in H37Rv-, GyrB E540A-, GyrB A543V-and GyrA A90V-infected mice (P , 0.0001) ( Figure S3) . A 66 mg/kg q6h moxifloxacin dose prevented mortality in GyrB E540A-, GyrB A543V-and GyrA A90V-infected mice (P " 0.01, P " 0.001 and P " 0.01, respectively) ( Figure S4) . A 66 mg/kg q6h moxifloxacin dose was more effective than a 50 mg/kg q6h levofloxacin dose in GyrB A543V-and GyrA A90V-infected mice (P " 0.004 and P " 0.002, respectively) but not in GyrB E540A and H37Rv-infected mice. A 60 mg/kg q6h moxifloxacin dose was more effective than a 100 mg/kg q6h levofloxacin dose in GyrA A90V-infected mice (P " 0.0001) but not in GyrB A543V-, GyrB E540A-and H37Rv-infected mice.
Lung cfu counts Figure 1 shows lung cfu variations between the day before and 4 weeks after treatment initiation, depending on FQ dose and M. tuberculosis strain. Compared with D0, a 50 mg/kg q6h levofloxacin dose reduced lung cfu counts by 2.4 log 10 cfu in H37Rv-infected mice (P " 0.02), whereas the counts increased in GyrB E540A-, GyrB A543V-and GyrA A90V-infected mice (P " 0.003, P " 0.001 and P " 0.0003, respectively). Compared with D0, a 100 mg/kg q6h levofloxacin dose reduced lung cfu counts by 3.0 log 10 cfu in H37Rv-infected mice (P " 0.0002), by 1.1 log 10 cfu in GyrB E540A-infected mice (P " 0.0002) and by 0.9 log 10 cfu in GyrB A543V-infected mice (P " 0.0003), whereas the counts increased in GyrA A90V-infected mice (P " 0.001).
Compared with D0, a 60 mg/kg q6h moxifloxacin dose reduced lung cfu counts by 3.7 log 10 cfu in H37Rv-infected mice (P " 0.0002), by 2.3 log 10 cfu in GyrB E540A-infected mice (P " 0.0002) and by 2.7 log 10 cfu in GyrB A543V-infected mice (P " 0.0002), whereas the counts tended to increase in GyrA A90V-infected mice (P " 0.07). Compared with D0, a 66 mg/kg q6h moxifloxacin dose reduced lung cfu counts by 3.4 log 10 cfu in H37Rv-infected mice (P " 0.001), by 2.1 log 10 cfu in GyrB E540A-infected mice (P " 0.0003) and by 1.6 log 10 cfu in GyrB A543V-infected mice (P " 0.00002) but not in GyrA A90V-infected mice, in which the cfu counts remained unchanged.
Mice infected with GyrB E540A, GyrB A543V and GyrA A90V and treated with 66 mg/kg q6h moxifloxacin had final lung cfu counts lower than those treated with 50 mg/kg q6h levofloxacin (P , 0.0004). Mice infected with each M. tuberculosis strain and treated with 60 mg/kg q6h moxifloxacin had final lung cfu counts lower than those treated with 100 mg/kg q6h levofloxacin (P , 0.01).
Bactericidal activities of levofloxacin and moxifloxacin against M. tuberculosis in a sigmoid-E max effect model Non-linear regression analyses showed a good fit for moxifloxacin in the AUC 0-24 /MIC exposure model (r 2 " 0.95) and in the C max /MIC exposure model (r 2 " 0.86) (Figure 2 ). For levofloxacin, non-linear regression analyses showed a lesser fit in the AUC 0-24 h /MIC exposure model (r 2 " 0.71) and in the C max /MIC exposure model (r 2 " 0.79) ( Figure 3 ). As shown, the levofloxacin dose-effect model exhibited an E max of 5 log 10 lung cfu reduction after 4 weeks with an EC 50 AUC 0-24 /MIC ratio of 110 and a C max /MIC ratio of 30. The moxifloxacin dose-effect model exhibited an E max of 6.5 log 10 lung cfu reduction after 4 weeks with an EC 50 AUC 0-24 /MIC ratio of 90 and a C max /MIC ratio of 10. The observed and calculated bactericidal effects of levofloxacin and moxifloxacin were statistically different in both the AUC 0-24 /MIC and the C max /MIC exposure models (P , 0.04). Maitre et al.
Discussion
Low-level resistance has been observed in vitro with many antibiotics for many years. In some cases, this low-level resistance allows successful use of antibiotics in vivo, as has been demonstrated with the tazobactam/piperacillin combination against ESBL-producing Enterobacteriaceae. 22 Regarding antituberculous drugs, there have been descriptions of various levels of resistance against many antibiotics including the major compounds such as rifampicin, isoniazid or FQs. 8, 13 Knowing the strong impact of FQ resistance on the prognosis of MDR TB, 5 and despite the risk of increasing FQ resistance by creating second-step mutants, 23 the use of FQs has been suggested in cases of low-level resistance. 11, 24 Data from clinical studies, including those on gatifloxacin or moxifloxacin, support the use of these drugs in cases of low-level resistance. In particular, it has been shown that a high-dose gatifloxacin-containing regimen (800 mg/day) is as active against gatifloxacin-susceptible strains as against strains with low-level gatifloxacin resistance (MIC , 2 mg/L). 8 In a murine model of tuberculosis we demonstrated that moxifloxacin retained bactericidal activity against strains with low-level resistance (GyrB D500N; MIC " 0.5 mg/L) and displayed bacteriostatic activity in cases of intermediate-level resistance (GyrA A90V; MIC " 2 mg/L) but was not active in cases of high-level resistance (GyrA D94G; MIC" 4 mg/L). 6 We subsequently demonstrated that a similar gradual decrease in activity was also measurable when moxifloxacin was included in a very active second-line regimen containing pyrazinamide, ethionamide and amikacin. 7 In the present work we wished to extend our previous studies to another FQ, levofloxacin, and to other low-level resistant mutants (GyrB E540A and GyrB A543V). Accumulating data on these low-level resistant strains is important since the choice to include a drug, although active in vitro, should be made with caution because of its possibly greater toxicity. Moreover, with the increase in genotypic diagnoses of resistance, therapeutic choices will be made increasingly on the basis of the genotype only, or will be based initially on the genotype and subsequently adapted to the phenotype. 25 The murine model offers a unique opportunity to compare the activity of human equivalent doses of FQs against isogenic mutants of the WT reference strain H37Rv.
The present study contributes information on the use of FQs in cases of FQ-resistant tuberculosis. One important finding was that, against strains with the GyrA A90V mutation, which is the second most frequently encountered 13 and which causes intermediatelevel resistance with moxifloxacin and levofloxacin MICs of 2 and 4 mg/L, respectively, both FQs had, at most, bacteriostatic activity even when mimicking high human doses, i.e. 800 mg/day moxifloxacin and 1000 mg/day levofloxacin. These results are concordant with the outcomes of patients infected with a strain harbouring the GyrA A90V substitution that were unfavourable in three of five cases. 24 Thus, the benefit of adding an FQ to a regimen used against a strain harbouring the GyrA A90V substitution is probably limited and, moreover, may increase FQ resistance by creating second-step mutants. 6, 23 Regarding the two GyrB mutants with low-level resistance (moxifloxacin and levofloxacin MICs " 0.5 and 1 mg/L), the efficacy of the drugs was variably dose dependent. While moxifloxacin was bactericidal independent of the dose, levofloxacin did not Table 2 . Levofloxacin or moxifloxacin for XDR tuberculosis?
JAC prevent bacterial growth at 50 mg/kg q6h (the human equivalent of 750 mg/day) but displayed bactericidal activity at 100 mg/kg q6h (the human equivalent of 1000 mg/day). Interestingly, for both GyrB mutants against which moxifloxacin and levofloxacin have reduced activity at conventional dosing, the respective MICs fall in the susceptible range according to WHO criteria. 26 Thus, if only a phenotypic diagnosis of resistance is made without genotypic analysis, low-level resistance in strains such as these may be overlooked. Taken together, these results suggest that the greatest benefit would be obtained with the use of moxifloxacin at 800 mg/day against strains with moxifloxacin MICs ,2 mg/L. The possibility of Maitre et al.
using FQs despite in vitro resistance depends on the relative abundance of different DNA gyrase mutants in a given population and on their phenotypic susceptibility. The genotypic or phenotypic methods used to measure FQ susceptibility vary in the literature. We believe that the percentage of cases in which moxifloxacin could be active-for example, cases caused by strains for which the MIC is ,2 mg/L-ranges between 30% and 90% of ofloxacinresistant MDR cases, depending on the methods used and on geographical variations. 13, 24, 27, 28 Another limitation of the use of moxifloxacin against FQ-resistant strains is inter-patient pharmacokinetic variability. 16, 29 Considering our results, levofloxacin appears to be a much less attractive option for the treatment of FQ-resistant strains. Indeed, based on our model, this FQ at the human equivalent dose of 750 mg/day should not have any activity, whereas at 1000 mg/day it would have activity against mutants of M. tuberculosis with levofloxacin MICs 1 mg/L. In particular, no activity is expected against the frequent GyrA A90V mutants. A higher dose of levofloxacin has been used recently (20 mg/kg) and may be an interesting option. 9, 30 A second important finding of this study concerns the difference in activity of moxifloxacin and levofloxacin against both FQ-resistant and FQ-susceptible strains. Moxifloxacin and levofloxacin have different pharmacokinetic profiles and in vitro activities. Moxifloxacin is more active than levofloxacin in vitro since its MICs for M. tuberculosis are usually one dilution lower. 31, 32 Conversely, levofloxacin has a better pharmacokinetic profile in humans, with both AUC and C max values 2-3 times higher than those determined for moxifloxacin. 14, 18, 33 Since the pharmacokinetic advantage of levofloxacin outweighed the MIC-related disadvantage, we expected that levofloxacin would have been more active than moxifloxacin. Surprisingly, the opposite was observed, with moxifloxacin being more active than levofloxacin against both FQ-resistant and FQ-susceptible strains.
In order to compare the two drugs, we correlated the respective AUC 0-24 /MIC and C max /MIC ratios to the cfu decrease (Table 3) . These ratios abolish the pharmacokinetic and MIC differences, merging them into a unique indicator of activity. Our moxifloxacin dose-effect model exhibited an E max of 6.5 log 10 lung cfu reduction and an EC 50 AUC 0-24 /MIC ratio of 90 after 4 weeks of treatment.
These data are in accordance with the AUC 0-24 /MIC target ratio of at least 100 suggested by Shandil et al. 21 The levofloxacin dose-effect model exhibited a lower E max (5 log 10 lung cfu reduction) with a higher EC 50 (AUC 0-24 /MIC ratio of 110). Thus, for the same exposure (AUC 0-24 /MIC and C max /MIC ratios), moxifloxacin was more bactericidal than levofloxacin.
This difference in activity between the two drugs could be explained in part by a difference in the effects of the anti-DNA gyrase activities of these two FQs. The FQ target is DNA gyrase, a ubiquitous enzyme that introduces negative supercoils into DNA and contributes to maintaining bacterial chromosome superstructure and integrity. Structural data revealed only few differences in levofloxacin-and moxifloxacin-enzyme interactions that involved the formation of a water/magnesium-ion bridge network between the enzyme and the C3/C4 keto acid of the FQs. On the other hand, cleaved-complex stability correlates well with in vivo efficacy and is likely to be related to the killing of M. tuberculosis cells. Thus, the better activity of moxifloxacin compared with levofloxacin could be correlated to its ability to promote the formation of more stable gyrase-DNA-FQ complexes. 34, 35 Thus, these results suggest that moxifloxacin should be the preferred FQ in an MDR TB regimen against both FQ-susceptible and FQ-resistant strains. At first view, these results seem to contradict those of a clinical study that has shown the equivalence at 3 months of two regimens containing either moxifloxacin, 400 mg/day, or levofloxacin, 750 mg/day, for the treatment of MDR TB. 10 However, previous studies in murine models of tuberculosis have shown that, despite differences at late time points (!6 months) there is no difference at early time points (2 or 3 months) between levofloxacin-or moxifloxacincontaining regimens. 36, 37 Thus, the superior activity of moxifloxacin shown here may also be seen in humans if the analysis were done at later time points.
This study had several limitations. First, FQ activities were assessed in mice over a 4 week monotherapy regimen. The better activity of moxifloxacin against FQ-resistant strains should be confirmed by further studies that assess it in a multidrug regimen for the treatment of XDR TB with various levels of phenotypic FQ resistance. Second, we noted early mortality in H37Rv-infected mice during the first study. This mortality, induced by JAC the intensive oral gavage regimen, was observed during the first 10 days among mice treated with 50 mg/kg q6h levofloxacin or 66 mg/kg q6h moxifloxacin. These mice were included in an intent-to-treat survival analysis in order not to underestimate the mortality of treated mice. These mice were excluded from lung cfu count analysis in order not to overestimate cfu counts in lungs of treated mice. Furthermore BALB/c mice develop a TB disease that is characterized by larger intracellular bacillary populations than those seen in humans. 38, 39 This difference may favour moxifloxacin over levofloxacin because of better intracellular penetration. 40, 41 Finally, it should be recalled here that there are other drugs, for example, quinazolinediones (diones), with the potential to circumvent common quinoloneresistance mutations. 42 In conclusion, the human equivalent high dose of moxifloxacin (800 mg/day) exhibited greater bactericidal activity in mice than that of levofloxacin (1000 mg/day) against susceptible or low-level FQ-resistant M. tuberculosis strains. In the absence of potential toxicity limiting its use, moxifloxacin should be preferred to levofloxacin for the treatment of MDR and XDR tuberculosis with lowlevel FQ resistance. 
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